Erlotinib hydrochloride
| Code | Size | Price |
|---|
| SYN-1039-M100 | 100 mg | Enquire |
Quantity:
| SYN-1039-M001 | 1 mg | £69.00 |
Quantity:
| SYN-1039-M005 | 5 mg | £92.00 |
Quantity:
| SYN-1039-M010 | 10 mg | £115.00 |
Quantity:
| SYN-1039-M050 | 50 mg | £151.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
OSI774; CP-358774; Tarceva; NSC718781
Appearance:
Solid.
CAS:
183319-69-9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS05,GHS07,GHS08,GHS09
Hazards:
H302, H315, H318, H351, H361, H373, H401, H411
InChi:
InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
InChiKey:
GTTBEUCJPZQMDZ-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 183319-69-9. Formula: C22H23N3O4 . HCl. MW: 393.4 . 36.5. Erlotinib inhibits EGFR tyrosine kinase auto-phosphorylation. Studies in cell lines and enzyme assays have shown that erlotinib inhibits EGFR at concentrations significantly lower than those needed to inhibit c-src and v-abl. It has an IC(50) of 2nM against EGFR. It is >1000-fold more sensitive for EGFR than for c-Src or v-Abl.
Molecular Formula:
C22H23N3O4 . HCl
Molecular Weight:
393.4 . 36.5
Package Type:
Plastic Vial
Precautions:
P264, P270, P301, P312, P330, P501, P280, P302, P352, P321, P332, P313, P362, P305, P351, P338, P310
Product Description:
Erlotinib inhibits EGFR tyrosine kinase auto-phosphorylation. Studies in cell lines and enzyme assays have shown that erlotinib inhibits EGFR at concentrations significantly lower than those needed to inhibit c-src and v-abl. It has an IC(50) of 2nM against EGFR. It is >1000-fold more sensitive for EGFR than for c-Src or v-Abl.
Purity:
>95%
Signal word:
Danger
Solubility Chemicals:
Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen: J.R. Johnson, et al.; Clin. Cancer Res. 11, 6414 (2005)
Related Products
| Product Name | Product Code | Supplier | Altenusin | AG-CN2-0143 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PD-173955-Analog1 | SYN-1062 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||